Pfizer Sues Over Generic For Arthritis Drug Xeljanz
Law360 (January 12, 2021, 6:09 PM EST) -- Pharmaceutical giant Pfizer has asked a Delaware federal court to block generic-drug maker Aurobindo Pharma from moving ahead with plans to sell a generic version of arthritis drug Xeljanz that Pfizer says would infringe two patents it owns.
Pfizer Inc. and three subsidiaries allege in the Monday filing that the Indian pharmaceutical maker is violating two patents for Xeljanz — a drug approved in 2012 that was designed to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — that don't expire for another two to four years.
Aurobindo Pharma Ltd. can't proceed with its abbreviated new drug application to market a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!